Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 445

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women

Open access
Cranney, Ann, Wells, George, Willan, Andrew, Griffith, Lauren, Zytaruk, Nicole, Robinson, Vivian, Black, Dennis, Adachi, Jonathan, Shea, Beverley, Tugwell, Peter, Guyatt, Gordon, The Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group · 2002 · Endocrine Reviews

Abstract

Objective: To review the effect of alendronate on bone density and fractures in postmenopausal women. Data Source: We searched MEDLINE, EMBASE, Current Contents, and the Cochrane Controlled trials registry from 1980 to 1999, and we examined citations of relevant articles and proceedings of international meetings. Study Selection: We included 11 trials that randomized women to alendronate or placebo and measured bone density for at least 1 yr. Data Extraction: For each trial, three independent reviewers assessed the methodological quality and abstracted data. Data Synthesis: The pooled relative risk (RR) for vertebral fractures in patients given 5 mg or more of alendronate was 0.52 [95% confidence interval (CI), 0.43–0.65]. The RR of nonvertebral fractures in patients given 10 mg or more of alendronate was 0.51 (95% CI 0.38–0.69), an appreciably greater effect than for the 5 mg dose. We found a similar reduction in RR across nonvertebral fracture types; in particular, RR reductions for fractures traditionally thought to be “osteoporotic,” such as hip and forearm, were very similar to RR reductions for “nonosteoporotic” fractures. Individual studies showed similar results, reflected in the P values of the test of heterogeneity (P = 0.99 for vertebral and 0.88 for nonvertebral fractures). Alendronate produced positive effects on the percentage change in bone density, which increased with both dose and time. After 3 yr of treatment with 10 mg of alendronate or more, the pooled estimate of the difference in percentage change between alendronate and placebo was 7.48% (95% CI 6.12–8.85) for the lumbar spine (2–3 yr), 5.60% (95% CI 4.80–6.39) for the hip (3–4 yr), 2.08% (95% CI 1.53–2.63) for the forearm (2–4 yr), and 2.73% (95% CI 2.27–3.20) for the total body (3 yr). Heterogeneity of the treatment effect of alendronate was not consistently explained by any of our a priori hypotheses; in particular, the effect was very similar in prevention and treatment studies. The pooled RR for discontinuing medication due to adverse effects for 5 mg or greater of alendronate was 1.15 (95% CI 0.93–1.42). The pooled RR for discontinuing medication due to gastro-intestinal (GI) side effects for 5 mg or greater was 1.03 (0.81–1.30, P = 0.83), and the pooled RR for GI adverse effects with continuation of medication was 1.03 (0.98 to 1.07) P = 0.23. Conclusions: Alendronate increases bone density in both early postmenopausal women and those with established osteoporosis while reducing the rate of vertebral fracture over 2–3 yr of treatment. Reductions in nonvertebral fractures are evident among postmenopausal women without prevalent fractures and have bone mineral density (BMD) levels below the World Health Organization threshold for osteoporosis. The impact on fractures appears consistent across all fracture types, casting doubt on traditional distinctions between osteoporotic and nonosteoporotic fractures. ALENDRONATE SODIUM, a bisphosphonate and antiresorptive agent, was developed and marketed as an intervention to reduce vertebral and nonvertebral fractures in postmenopausal women (1–3). Alendronate does not impair bone mineralization at doses that maximally inhibit bone resorption (4). A previous systematic review examining the effect of alendronate on nonvertebral fractures (2) did not clearly report their search methods, address the methodological quality of the individual trials, include unpublished data, or examine the effect on vertebral fractures or BMD. Furthermore, the 95% CI on the RR bordered on no effect (0.50–1.0). We therefore undertook a systematic review and meta-analysis of the effect of alendronate on bone density and fractures. An additional motivation for the review was to explore whether the effect of alendronate was consistent across studies, and whether results differed in those with milder vs. more severe osteoporosis, those ingesting more or less calcium or vitamin D, across different doses and durations of alendronate therapy, and in different fracture sites. We followed the procedures defined by the Cochrane Collaboration for conducting a systematic review (5). Trials satisfied the following inclusion criteria: 1) randomized placebo-controlled trials (RCTs) comparing postmenopausal women receiving alendronate to those not receiving alendronate with follow-up of at least 1 yr; and 2) fracture incidence, or BMD data (including percentage change from baseline and a measure of variance) available. We made no restriction by country in which the trial occurred, nor did we limit the language to English. Eleven trials total met our inclusion criteria (1, 3, 6–12, 15, 14). To identify relevant studies of alendronate therapy, we used the search strategy outlined in Section I and used the following key and text words: bisphosphonates, diphosphonates, osteoporosis, postmenopausal, and alendronate (15). We reviewed citations of relevant articles and conference proceedings. Two reviewers (A.C., V.R.) examined each t

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2001-2002

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Metadata

Authors
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., Guyatt, G., The Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group
Venue
Endocrine Reviews
Published
2002-08-01
Volume
23
Issue
4
Pages
508-516
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2126070576
Cited by
445
References
28
FWCI
5.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.